iiinova — where your digital self keeps evolving

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 40m

How do signaling networks guide #CellDifferentiation in health and disease? This review explores Wnt, Notch, Hedgehog, TGF-β, and Hippo pathways, their regulatory crosstalk, disease roles, and potential for targeted therapies. #STTT #OpenAccess: doi.org/10.1038/s413...

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 6h

Researchers uncover an HPGDS–PGD2 pathway that promotes pathogenic Th17 differentiation by antagonizing PPARγ, while HPGDS inhibition suppresses Th17 responses and alleviates #Autoimmune pathology in #MultipleSclerosis models. #STTT #OpenAccess: doi.org/10.1038/s413... #DiseaseDetection

Targeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 10h

A phase I trial evaluates CNSI-Fe, a carbon #Nanoparticle–Fe(II) complex that delivers Fe iron directly into tumors to trigger #Cancer cell #Ferroptosis, showing a favorable safety profile and preliminary antitumor activity. #STTT #OpenAccess: doi.org/10.1038/s413...

$Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I trial$

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 20h

Modulating #BACE1 transcription offers a different route to targeting #Amyloid pathology. Chlorhexidine suppresses BACE1 via a SOCS3-dependent JAK/STAT response, reducing amyloid pathology and cognitive deficits in AD models. #STTT #OpenAccess: doi.org/10.1038/s413... #CellTherapy

Transcriptional modulation of β-Secretase ameliorates amyloid pathology and cognitive deficits in Alzheimer’s disease models

011

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 03/10/2026

Can gingiva-derived MSCs (GMSCs) help preserve β-cell function in #Type1Diabetes (#T1DM)? A phase 1 trial links GMSC therapy to improved residual β-cell function, potentially through CD8+ T-cell exhaustion. #STTT #OpenAccess: doi.org/10.1038/s413... #CellTherapy #BetaCellFunction

Safety and efficacy of human gingiva-derived mesenchymal stem cells in patients with type 1 diabetes: a double-blind, randomized, placebo-controlled, phase 1 trial

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 03/10/2026

Infection and hypoxic stress converge on the PHD1–TRIM21–CDC20 axis, promoting CDC20 degradation and securin and MCL1 accumulation to drive cancer cell #Aneuploidy and #Chemoresistance. #STTT #OpenAccess: doi.org/10.1038/s413...

Infection and α-ketoglutarate/oxygen inhibition converge to CDC20 to promote cancer cell aneuploidy

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 03/10/2026

CDK12/13 inhibition exposes a vulnerability in platinum-resistant #OvarianCancer by disrupting transcription and #AlternativeSplicing, with the CDK12–SFPQ/p54nrb complex driving RNA-processing reprogramming and cytotoxicity. #STTT #OpenAccess: doi.org/10.1038/s413...

CDK12/13 inhibition overcomes platinum resistance by impairing RNA metabolism

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 02/10/2026

Muscle cells retain intrinsic #miRNA alterations in #Type2Diabetes. T2D-derived myoblasts show altered miRNA expression and sEV secretion linked to metabolic pathways, while their sEVs fail to enhance adipocyte metabolic function. @harvardmed.bsky.social #STTT #OpenAccess: doi.org/10.1038/s413...

miRNAs as cell-intrinsic epigenetic regulators in muscle in type 2 diabetes

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 02/10/2026

Mycobacterium abscessus directly links the #TumorMicrobiome to #NSCLC mutagenesis, as bacterial NDK phosphorylates IRF3 to amplify interferon signaling and sustain #APOBEC3A-driven genomic diversification. #STTT #OpenAccess: doi.org/10.1038/s413...

Intratumoral Mycobacterium abscessus promotes cytidine deaminase mutagenesis in non-small cell lung cancer

132

Reposted by Signal Transduction and Targeted Therapy

ESMO - European Society for Medical Oncology @myesmo.bsky.social · 01/10/2026

📣 Abstract submission for #ELCC27 is now open. Share your research with a focused, multidisciplinary thoracic oncology community. Gain valuable feedback, increase the visibility of your work and start new collaborations. 🔗 Submit now - ow.ly/Jrtf50ZTpbk

143

Reposted by Signal Transduction and Targeted Therapy

American Association for Cancer Research (AACR) @theaacr.bsky.social · 01/10/2026

Abstract submission is now open for the AACR Annual Meeting 2027 (April 2-7). Submit your abstract by November 10 and join us in Orlando to share the latest advances in cancer science and medicine. Learn more: buff.ly/WuSSXNE #AACR27

022

Reposted by Signal Transduction and Targeted Therapy

OncLive @onclive.bsky.social · 01/10/2026

🎙️ In case you missed any, read a recap of the episodes of #OncliveOnAir that aired in September 2026. @lpetrillz.bsky.social @matthewkurianmd.bsky.social #oncology #hematology Read the full recap ➡️: www.onclive.com/view/revisit...

onclive.com

Revisit Every OncLive On Air Episode From September 2026 | OncLive

In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.

011

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 02/10/2026

The phase 3 ANCHOR trial finds that anlotinib + CapeOX shows similar antitumor activity to bevacizumab + CapeOX in RAS/BRAF wild-type #Metastatic #ColorectalCancer, but does not meet the prespecified noninferiority margin for PFS. #STTT #OpenAccess: doi.org/10.1038/s413...

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 02/10/2026

The phase 3 ICWIP #ClinicalTrial shows that three-year adjuvant icotinib following #Chemotherapy significantly improves disease-free survival versus placebo in completely resected stage II–IIIA disease, with a manageable safety profile. #STTT #OpenAccess: doi.org/10.1038/s413...

Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 01/10/2026

miR-150 fine-tunes stem cell fate through dual control of #SOX2, regulating its mRNA stability and #Autophagy-mediated degradation via the KLHL20–ULK1 axis to balance ectodermal and mesodermal lineage commitment. #STTT #OpenAccess: doi.org/10.1038/s413...

Dual-mode SOX2 regulation by miR-150 via mRNA suppression and autophagy controls stem cell fate

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 01/10/2026

RAC1 #SUMOylation emerges as a druggable regulator of #BreastCancer #Metastasis. Blocking this switch with TAT-PRASI reduces RAC1 activity and RAC1–POTEE interaction, impairing invadopodia formation and metastatic invasion. @usaloficial.bsky.social @ucm.es #STTT #OpenAccess: doi.org/10.1038/s413...

A RAC1 SUMOylation switch governs breast cancer metastasis

010

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 01/10/2026

A multitarget strategy may help address #TNBC heterogeneity. Opti-hTIF1γ suppresses β-catenin, TGFβ and STAT3 signaling while downregulating CD47 and CXCL5, enhancing #macrophage phagocytosis and #antitumoractivity. #TumorMicroenvironment #CancerBiology #STTT #OpenAccess: doi.org/10.1038/s413...

Transcriptional intermediary factor 1 gamma-based multitarget gene therapeutic strategy for triple-negative breast cancer

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 01/10/2026

This study uncovers how polymeric #Alpha1Antitrypsin accumulation perturbs Paneth cell #Proteostasis via #ERstress and impaired lysosomal clearance, linking deficiency to severe intestinal inflammation. #STTT #OpenAccess: doi.org/10.1038/s413...

Polymeric alpha-1 antitrypsin perturbs Paneth cell proteostasis and exacerbates intestinal inflammation

001

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 30/09/2026

Learn how all-trans retinoic acid prevents CD8+ T-cell exhaustion and potentiates anti-PD-1 therapy in #Glioblastoma by activating WNT/β-catenin–TCF-1βBD signaling. #STTT #OpenAccess: doi.org/10.1038/s413... #CancerResearch #TranslationalMedicine

All-trans retinoic acid suppresses CD8+ T-cell terminal exhaustion and potentiates anti-PD-1 therapy in glioblastoma

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 30/09/2026

How does macrophage zinc accumulation worsen #MASLD progression? Macrophage zinc trapping activates IRE1α–XBP1s signaling, promoting IL-1β-driven #MetabolicReprogramming and lipid transfer to hepatocytes, driving liver inflammation. #STTT #OpenAccess: doi.org/10.1038/s413...

Zinc accumulation in macrophages exacerbates metabolic dysfunction-associated steatotic liver disease progression

020

Reposted by Signal Transduction and Targeted Therapy

American Association for Cancer Research (AACR) @theaacr.bsky.social · 29/09/2026

Register by October 27 to get the lowest rates for the AACR Conference on Advances in the Pathogenesis and Immune Therapies of Liver Cancer (December 6-8; Austin, Texas), chaired by Richard S. Finn, Josep M. Llovet, and Jessica Zucman-Rossi. buff.ly/QuyRLts #AACRliver26 @zucmanrossi.bsky.social

022

Reposted by Signal Transduction and Targeted Therapy

OncLive @onclive.bsky.social · 30/09/2026

WATCH 🎥: Meredith Pelster, MD, MSCI, discusses the biomarker-agnostic design of the phase 3 MAPKeeper 301 trial of atebimetinib in metastatic pancreatic cancer. #pancsm #oncology Full video ➡️: www.onclive.com/view/dr-pels...

onclive.com

Dr Pelster on the MAPKeeper 301 Trial Evaluating Atebimetinib in First-Line Metastatic Pancreatic Cancer | OncLive

Meredith Pelster, MD, MSCI, discusses the biomarker-agnostic design of the phase 3 MAPKeeper 301 trial of atebimetinib in metastatic pancreatic cancer.

021

Reposted by Signal Transduction and Targeted Therapy

raechel-mckinley.bsky.social @raechel-mckinley.bsky.social · 29/09/2026

The inaugural Molecular Bioscience Week is happening next week! Join the @asbmb.bsky.social to celebrate the wonders of foundational research! Register for MBSW events here: www.asbmb.org/molecular-bi...

asbmb.org

Molecular Bioscience Week

044

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 30/09/2026

Quiescent #BreastCancer stem-like cells can reawaken in #TNBC. New study in #STTT identifies an ENO1–lactate–H4K12la feedback loop that upregulates PCNA to activate qsBCSCs, revealing a metabolic–epigenetic axis linked to tumor growth. #OpenAccess: doi.org/10.1038/s413...

Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 30/09/2026

The anti-TFRC antibody PPMX-T003 suppresses #ColorectalCancer growth and metastatic colonization in preclinical models, highlighting iron-dependent tumor survival as a target for limiting metastatic progression. #STTT #OpenAccess: doi.org/10.1038/s413... #AntibodyTherapy #TargetedTherapy

Clinical-stage human anti-transferrin receptor antibodies suppress colorectal cancer metastasis

001

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 29/09/2026

Traditional #Biomarker discovery suffers from single-modality analyses, weak mechanistic foundations, and low reproducibility. This review examines #AI approaches for precision diagnostics and targeted therapies. #STTT #OpenAccess: doi.org/10.1038/s413... #DrugDelivery

Artificial intelligence in biomarker discovery for diseases: diagnostic and therapeutic prospects

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 29/09/2026

How can functional RNA molecules move beyond simple protein coding to power next-gen loss- and gain-of-function treatments? This review explores emerging druggable RNAs, optimization, and delivery systems for #clinicaltherapeutics. #STTT #OpenAccess: doi.org/10.1038/s413... #DrugDelivery

RNA therapeutics: current status and future directions

021

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 29/09/2026

TKTL1-driven #Glycolysis increases lactate and promotes #Immunosuppressive dendritic-cell signaling in #HCC. Targeting the TKTL1–HIF-1α–HK2 axis and lactate reprograms the #TumorMicroenvironment to enhance PD-1 blockade. #STTT #OpenAccess: doi.org/10.1038/s413...

Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 29/09/2026

Inotodiol activates LXRβ and promotes PPARδ-dependent #SIRT3 transcription, engaging the LXRβ/SIRT3/PGC-1α pathway to restore mitochondrial function and counter age-associated #MuscleWasting and #MetabolicDysfunction. #STTT #OpenAccess: doi.org/10.1038/s413...

Inotodiol prevents age-related muscle wasting by restoring mitochondrial function through liver X receptor beta signaling

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 28/09/2026

How do #Cuproptosis and #Ferroptosis intersect across disease? This review connects metal metabolism, redox imbalance, organelle crosstalk, and regulatory networks with therapeutic strategies, #Biomarkers, and patient stratification. #STTT #OpenAccess: doi.org/10.1038/s413... #PrecisionOncology

Cuproptosis and ferroptosis: signal pathways, diseases and therapeutic targets

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 28/09/2026

How can targeting synthetic lethal interactions revolutionize #Cancer treatment? This review examines PARP, ATR, ATM, DNA-PK, and emerging non-DDR targets, while addressing resistance, combination strategies, and patient selection. @uab.cat #Biomarkers #STTT #OpenAccess: doi.org/10.1038/s413...

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation

010

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 28/09/2026

ADC development requires coordinated optimization of antigens, antibodies, linkers, and payloads. This review explores how AI and computational #Biophysics can guide rational design, patient stratification, #Pharmacokinetics, and dosing.#DrugDesign #STTT #OpenAccess: doi.org/10.1038/s413...

Antibody-drug conjugate engineering: from design to efficacy and safety

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 28/09/2026

#Cancer heterogeneity operates across interconnected biological scales. The HITET framework links them through niche–flow–feedback interactions to organize mechanisms, therapeutic strategies, and hypotheses for future validation.#CancerGenomics #STTT #OpenAccess: doi.org/10.1038/s413...

Heterogeneity in cancer: molecular mechanisms and therapeutic strategies

010

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 27/09/2026

#FractureRepair relies on coordinated immune, vascular, neural, and skeletal signaling. This review connects key mechanisms of #BoneHealing with targeted regenerative strategies and their translational challenges. #STTT #OpenAccess: doi.org/10.1038/s413... #MotorDysfunction #CellBiology

Fracture healing: from molecular and cellular mechanisms to therapeutic strategies

010

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 27/09/2026

Can precision retinoid therapy overcome therapeutic resistance? This review defines “retinoid endotypes” shaped by metabolic niches, chromatin state, and #microenvironmental cues to inform patient stratification and precision therapy. #STTT #OpenAccess: doi.org/10.1038/s413... #Immunology

000

Reposted by Signal Transduction and Targeted Therapy

American Association for Cancer Research (AACR) @theaacr.bsky.social · 25/09/2026

Register by December 15 to get the lowest rates for the AACR Special Conference on Redefining Lung Cancer (January 14-17; San Diego), held in association with the AACR Lung Cancer Task Force and chaired by Charles Swanton. Learn more: buff.ly/hGLGu07 #AACRlung27 @charlesswanton.bsky.social

022

Reposted by Signal Transduction and Targeted Therapy

American Association for Cancer Research (AACR) @theaacr.bsky.social · 25/09/2026

The AACR Conference on New Frontiers in the Biology of and Therapeutic Development for Pancreatic Cancer opens this evening in San Diego with a keynote lecture by Andrew J. Aguirre. #AACRpan26

083

Reposted by Signal Transduction and Targeted Therapy

OncLive @onclive.bsky.social · 25/09/2026

Is surgery becoming the adjuvant step in colorectal cancer? In this episode of #OncologyUnplugged 🔌, Chandler Park, MD, and Pashtoon Kasi, MD, MS, unpack neoadjuvant immunotherapy, from NICHE to NEST, dMMR to MSS, and ctDNA as an emerging end point. 🎧 onclive.com/view/neoadju... #crcsm

onclive.com

Neoadjuvant Immunotherapy and Short Treatment Courses Drive Paradigm Shifts in CRC Management | OncLive

Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.

011

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 27/09/2026

USP2 inhibition destabilizes STUB1 to suppress pathological #Pexophagy in PEX1-deficient models, restoring peroxisome abundance while mitigating metabolic abnormalities, neuro-axonal pathology, and motor dysfunction. #STTT #OpenAccess: doi.org/10.1038/s413... #Neurobiology #MolecularMedicine

Inhibition of USP2 suppresses pathological pexophagy and rescues PEX1-deficient peroxisome biogenesis disorder

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 27/09/2026

Researchers show that targeting BIRC6 disrupts a Treg-driven pathway that supports aged HSC survival, helping rebalance #hematopoiesis, reduce #Immunosenescence, and improve immune function in models of #Aging. #STTT #OpenAccess: doi.org/10.1038/s413... #Hematology #Immunology

Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence

020

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 26/09/2026

Single-cell #Multiomics reveals that #TNBC-derived #Exosomes reshape T cells through regulatory and dysfunctional states, #miRNA-mediated immune suppression, and distinct γδ and αβ TCR clonotypic expansions. #STTT #OpenAccess: doi.org/10.1038/s413...

Single-cell multiomics reveals exosome-mediated reprogramming and clonotypic remodeling of T cells in triple-negative breast cancer

012

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 26/09/2026

Researchers combine allele-specific #Genomics with an AI-based histopathology model to identify RB1-Bi tumors and uncover synthetic lethal vulnerabilities to mitotic and DNA damage response inhibitors. #STTT #OpenAccess: doi.org/10.1038/s413...

Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy

020

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 26/09/2026

The TRAINER phase II study evaluates #Biomarker-driven total #Neoadjuvant therapy with bevacizumab or cetuximab for high-risk #RectalCancer, reporting complete responses and high sphincter preservation. #STTT #OpenAccess: doi.org/10.1038/s413...

A multicohort, biomarker-driven phase 2 trial of personalized total neoadjuvant therapy with targeted agents for high-risk rectal cancer (The TRAINER study)

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 26/09/2026

#Fructose directly binds TOM22 and remodels the mitochondrial TOM complex, disrupting protein import, ribosome biogenesis, and #OxidativePhosphorylation, revealing a metabolism-independent mechanism of #Podocyte injury. @tsinghuauniversity.bsky.social #STTT #OpenAccess: doi.org/10.1038/s413...

Fructose directly remodels the translocase of the outer membrane to impair oxidative phosphorylation in podocytes

011

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 25/09/2026

A randomized phase II trial reveals that once-daily nonpeptide VCT220 reduced #bodyweight vs placebo while improving metabolic measures, with mainly mild-to-moderate #gastrointestinal adverse events supporting further evaluation. @pku1898.bsky.social #STTT #OpenAccess: doi.org/10.1038/s413...

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

000

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 25/09/2026

Findings from a randomized phase III #ClinicalTrial showed that mefatinib improved progression-free survival vs gefitinib, with a pronounced benefit in #EGFR L858R-mutated #NSCLC and comparable outcomes in exon 19 deletion. #STTT #OpenAccess: doi.org/10.1038/s413...

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

000

Reposted by Signal Transduction and Targeted Therapy

American Association for Cancer Research (AACR) @theaacr.bsky.social · 24/09/2026

Sumera Ilyas, Daniela Sia, Arndt Vogel, and Robin Kate Kelly will discuss "Molecular Pathogenesis and Therapies in Cholangiocarcinoma" in a plenary session at the AACR Conference on Liver Cancer (December 6-8; Austin). buff.ly/gwHhSQQ #AACRliver26 @arndtvogel.bsky.social

011

Reposted by Signal Transduction and Targeted Therapy

OncLive @onclive.bsky.social · 25/09/2026

WATCH 📺: In this episode of #OncLiveOnAir 🎙️, Narjust Florez, MD, of @danafarber.bsky.social, and Jonathan Wesley Riess, MD, MS, of @ucdavis.bsky.social, discuss HER2 overexpression vs HER2 mutations in NSCLC. #lcsm #oncology Watch or listen ➡️: www.onclive.com/view/recent-...

onclive.com

Recent Data Readouts Help Untangle HER2 Overexpression and Mutation Implications in NSCLC | OncLive

Drs Florez and Riess discuss the distinction between HER2 overexpression and HER2 mutations in non–small cell lung cancer.

011

Reposted by Signal Transduction and Targeted Therapy

European Society for Radiotherapy and Oncology (ESTRO) @estroradiotherapy.bsky.social · 24/09/2026

🧠 EANO-ESTRO Joint Session at #EANO2026 Join “Toward Precision and Cognitive-Sparing Radiotherapy in Gliomas” and hear from the ESTRO speakers 📅 27 Sep | 🕘 09:00–10:30 CEST 📍 Sinopoli Hall, Rome 👉 bit.ly/4hJiFy7 #ESTRO #EANO #Radonc

044

Signal Transduction and Targeted Therapy @sigtrans-sttt.bsky.social · 25/09/2026

Researchers harness the intracellular #Immunoproteasome as a disease-selective trigger, coupling #MMAE to an immunoproteasome-selective peptide to enable preferential drug release in #Cancer cells and suppress small cell #LungCancer. @uclacollege.bsky.social #OpenAccess: doi.org/10.1038/s413...

From probe to prodrug: immunoproteasome activity as a trigger for disease-selective therapeutics

000